Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 2, 2025
Product Development
VEGF bispecifics make inroads in other cancers, and more: Clinical Report
Plus: The week’s gainers and decliners after data
BioCentury | Jan 28, 2025
Emerging Company Profile
Isomab: Rebalancing VEGF-A isoforms to promote blood vessel formation
University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Jul 18, 2024
Data Byte
New AMD data showcase the promise and high bar for vectorized biologics
Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling
BioCentury | Nov 8, 2023
Deals
BioNTech looks to Biotheus again, this time for bispecific-ADC combo
German biotech’s second deal with Biotheus marks its fifth in-licensing agreement this year with a Chinese biotech
BioCentury | Oct 27, 2023
Politics, Policy & Law
Oct. 27 Quick Takes: AbbVie pegs IRA cost at $2.1 billion
Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more
BioCentury | May 26, 2023
Data Byte
CHMP seeks to pull Adakveo’s conditional approval; drug has full FDA approval
EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroya
BioCentury | Feb 8, 2023
Discovery & Translation
Expanding the base editor toolkit; plus new antibody discovery platforms and more
BioCentury’s roundup of translational news
BioCentury | Aug 19, 2022
Finance
Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal
First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
Items per page:
1 - 10 of 207